Piramal Critical Care has announced a distribution partnership with US-based pharmaceutical outsourcing facility, Medivant Healthcare, to help address a shortage of injectable drugs to treat COVID-19 in hospitals across the US, the company said on Wednesday.
The two companies said that through the partnership, they will work together to distribute single-dose injectable drugs in approved states for COVID-19 patients that have fallen dangerously short in supply.
Peter DeYoung, PCC chief executive officer, said that with the disruption caused by the pandemic, his company had observed an acute shortage of certain key injectable drugs in the US: “Our partnership with Medivant Healthcare will leverage our robust nationwide US marketing and distribution capabilities that will enable supply of single-dose injectable products to critical and sensitive markets for immediate use.”
PCC, a business unit of Piramal Enterprises, manufactures inhalation anaesthetics and injectable pain and anaesthesia drugs among others while Medivant is one of the US's newest outsourcing facilities focused on providing hospitals and doctors with single dose sterile injectable drugs on the US Food and Drug Administration's Drug Shortage List.
Piramal Critical Care has a marketing and sales team with a strong footprint across the United States, serving nearly all hospitals and surgical facilities nationwide.
“Coupling our focus on producing critical shortage medications with PCC's extensive market reach, I am confident that together we will play an integral role in helping hospitals across the country alleviate these acute drug shortages,” said founder and director of Medivant Healthcare, Viraj Gandhi.